Search clinical trials for: NUV001

Total 67 results

Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
LGD
ProRelix Services LLP

Recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
LGD
Assistance Publique Hopitaux De Marseille; CEN Biotech; Etablissement Français...

Recruiting

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Sickle Cell Disease

France
AiViva BioPharma, Inc.

Completed

A Safety and Efficacy Study to Evaluate Wound Healing

Wound Heal

United States
Chipscreen Biosciences, Ltd.

Not yet recruiting

A Study of NWY001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Norgine

Completed

Study of Escalating Doses of NRL001 Given in Slow-release Rectal Suppositories of Different Weights

Incontinence

United Kingdom
Neovia Oncology Ltd.

Recruiting

A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

Advanced Cancer | Solid Tumors

United States
AiViva BioPharma, Inc.

Completed

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Keloid

United States
Navidea Biopharmaceuticals

Terminated

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Liveome Inc.

Recruiting

A Study of LIV001 in Healthy Subjects and Those With Mild-to-Moderate Active Ulcerative Colitis (UC)

Ulcerative Colitis

Australia
AiViva BioPharma, Inc.

Withdrawn

A Safety and Efficacy Study to Evaluate Rosacea

Papulopustular Rosacea

United States
Navidea Biopharmaceuticals

Withdrawn

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

Parkinson's Syndrome

United States
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days

Fecal Incontinence

United Kingdom
Norgine

Completed

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects

Fecal Incontinence

United Kingdom
Promius Pharma, LLC

Terminated

Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States, Dominican Republic
Norgine

Completed

Effect of 7 Days of Dosing With a 10 mg Rectal Suppository of NRL001in Patients With Faecal Incontinence

Fecal Incontinence

United Kingdom
Promius Pharma, LLC

Terminated

Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails

Onychomycosis

United States
Norgine

Completed

Safety and Tolerability of a Single Intra-anal Dose of NRL001 in Healthy Volunteers

Fecal Incontinence

Bulgaria
Shanghai East Hospital
Shanghai Juvensis Therapeutics Biotechnology Company Limited

Recruiting

Myocardial Telomere Recapping Study for Dilated Cardiomyopathy (MERCURY-DCM)

Heart Failure | Dilated Cardiomyopathy

China
Purinomia Biotech, Inc.

Recruiting

Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Shanghai Synvida Biotechnology Co.,Ltd.

Recruiting

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Idiopathic Pulmonary Fibrosis

China
Neuraltus Pharmaceuticals, Inc.

Completed

A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Neuraltus Pharmaceuticals, Inc.

Completed

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

United States
Wuxi No. 4 People's Hospital

Not yet recruiting

Safety Study of 89Zr-NY001 PET Imaging in Patients

Solid Tumor, Adult

China
Neuraltus Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

Amyotrophic Lateral Sclerosis

United States, Canada
Beau Nakamoto
Neuraltus Pharmaceuticals, Inc.

Terminated

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Alzheimer Disease

United States
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis (CAMEO)

Primary Sclerosing Cholangitis (PSC)

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
Norgine

Completed

Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

Fecal Incontinence

United Kingdom
Rejuven Dermaceutical Co., Ltd.

Completed

RJV001 Study in Adults Receiving Abdominoplasty

Submental Fat (SMF) | Double Chin

United States
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, United Kingdom, Poland, France
Mirum Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network

Completed

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (ITCH)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
Sumagen

Completed

Safety and Immune Response Assessment Study of Killed-whole HIV-1 Vaccine (SAV001-H) in Chronic HIV-1 Infected Patients

HIV Infections

United States
Mirum Pharmaceuticals, Inc.

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) (IMAGINE)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.; Childhood Liver Disease Research and Education...

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
RVAC Medicines (US), Inc.

Terminated

Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273

COVID-19 | Infectious Disease

Australia
ARTBIO Inc.

Completed

Phase 0/1 Study of 212Pb-NG001 in mCRPC

Metastatic Castration-resistant Prostate Cancer

Norway
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Nitto Denko Corporation

Completed

Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers

Influenza

Japan
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
Mirum Pharmaceuticals, Inc.

Completed

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK)

Biliary Atresia

United States, United Kingdom, China, Taiwan, Germany, Poland, Singapore, Vietnam
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Completed

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Healthy Volunteers

United States
University of Chile

Unknown

Efficacy and Safety of Snail Slime and Natural Extracts for Healing in Diabetic Foot Ulcers

Diabetic Foot Ulcer

Chile

3

Subscribe